Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 128
Filtrer
1.
Clin Infect Dis ; 2024 Aug 13.
Article de Anglais | MEDLINE | ID: mdl-39136555

RÉSUMÉ

We describe our approach to addressing a nation-wide supply issue for blood culture bottles. Aerobic blood culture bottles received from our distributor July 1-15, 2024 was <1% of typical usage. Through education and ordering restrictions blood culture designed to minimize risk, orders were reduced by 49% over a one-week period.

2.
Antimicrob Agents Chemother ; 68(4): e0150723, 2024 Apr 03.
Article de Anglais | MEDLINE | ID: mdl-38376188

RÉSUMÉ

Carbapenem resistance due to metallo-ß-lactamases (MBLs) such as the Verona integron-encoded metallo-ß-lactamase (VIM) is particularly problematic due to the limited treatment options. We describe a case series of bacterial infections in a tertiary care hospital due to multi-species acquisition of a VIM gene along with our experience using novel ß-lactam antibiotics and antibiotic combinations to treat these infections. Four patients were treated with the combination of ceftazidime-avibactam and aztreonam, with no resistance to the combination detected. However, cefiderocol-resistant Klebsiella pneumoniae isolates were detected in two out of the five patients who received cefiderocol within 3 weeks of having started the antibiotic. Strain pairs of sequential susceptible and resistant isolates from both patients were analyzed using whole-genome sequencing. This analysis revealed that the pairs of isolates independently acquired point mutations in both the cirA and fiu genes, which encode siderophore receptors. These point mutations were remade in a laboratory strain of K. pneumoniae and resulted in a significant increase in the MIC of cefiderocol, even in the absence of a beta-lactamase enzyme or a penicillin-binding protein 3 (PBP3) mutation. While newer ß-lactam antibiotics remain an exciting addition to the antibiotic armamentarium, their use must be accompanied by diligent monitoring for the rapid development of resistance.


Sujet(s)
Unités de soins intensifs de brûlés , , Humains , Ceftazidime , Antibactériens/pharmacologie , bêta-Lactamases/génétique , bêta-Lactamases/métabolisme , Klebsiella pneumoniae , Association médicamenteuse , Composés azabicycliques , Carbapénèmes/pharmacologie , Épidémies de maladies , Tests de sensibilité microbienne
3.
Article de Anglais | MEDLINE | ID: mdl-38028891

RÉSUMÉ

A cluster of Rhizobium radiobacter isolates isolated from six unique surgical tissue cultures prompted an investigation ultimately identifying a pseudo-outbreak linked to errant laboratory tissue processing with contaminated, nonsterile saline. Timely response and multidisciplinary collaboration led to tangible system-level interventions and avoidance of unnecessary antibiotic exposures.

5.
Infect Control Hosp Epidemiol ; 44(11): 1816-1822, 2023 Nov.
Article de Anglais | MEDLINE | ID: mdl-37073852

RÉSUMÉ

OBJECTIVE: To provide comprehensive population-level estimates of the burden of healthcare-associated influenza. DESIGN: Retrospective cross-sectional study. SETTING: US Influenza Hospitalization Surveillance Network (FluSurv-NET) during 2012-2013 through 2018-2019 influenza seasons. PATIENTS: Laboratory-confirmed influenza-related hospitalizations in an 8-county catchment area in Tennessee. METHODS: The incidence of healthcare-associated influenza was determined using the traditional definition (ie, positive influenza test after hospital day 3) in addition to often underrecognized cases associated with recent post-acute care facility admission or a recent acute care hospitalization for a noninfluenza illness in the preceding 7 days. RESULTS: Among the 5,904 laboratory-confirmed influenza-related hospitalizations, 147 (2.5%) had traditionally defined healthcare-associated influenza. When we included patients with a positive influenza test obtained in the first 3 days of hospitalization and who were either transferred to the hospital directly from a post-acute care facility or who were recently discharged from an acute care facility for a noninfluenza illness in the preceding 7 days, we identified an additional 1,031 cases (17.5% of all influenza-related hospitalizations). CONCLUSIONS: Including influenza cases associated with preadmission healthcare exposures with traditionally defined cases resulted in an 8-fold higher incidence of healthcare-associated influenza. These results emphasize the importance of capturing other healthcare exposures that may serve as the initial site of viral transmission to provide more comprehensive estimates of the burden of healthcare-associated influenza and to inform improved infection prevention strategies.


Sujet(s)
Grippe humaine , Humains , Grippe humaine/diagnostic , Grippe humaine/épidémiologie , Grippe humaine/complications , Études transversales , Études rétrospectives , Hospitalisation , Surveillance de la population
6.
Infect Control Hosp Epidemiol ; 44(7): 1167-1170, 2023 Jul.
Article de Anglais | MEDLINE | ID: mdl-36155109

RÉSUMÉ

Academic hospital nurses were surveyed to assess adherence barriers to a universal povidone-iodine nasal decolonization protocol to prevent Staphylococcus aureus infection. Low training rates, inadequate supplies, documentation and tracking challenges, patient refusal, and burnout contributed to suboptimal adherence. Prioritizing education is essential but alone is insufficient for successful protocol adoption.


Sujet(s)
Staphylococcus aureus résistant à la méticilline , Infections à staphylocoques , Humains , Povidone iodée/usage thérapeutique , Staphylococcus aureus , Patients hospitalisés , Infections à staphylocoques/traitement médicamenteux , Infections à staphylocoques/prévention et contrôle , Nez , Antibactériens , Mupirocine , État de porteur sain
7.
Infect Control Hosp Epidemiol ; 44(1): 68-74, 2023 01.
Article de Anglais | MEDLINE | ID: mdl-36533305

RÉSUMÉ

BACKGROUND: Admission laboratory screening for asymptomatic coronavirus disease 2019 (COVID-19) has been utilized to mitigate healthcare-associated severe acute respiratory coronavirus virus 2 (SARS-CoV-2) transmission. An understanding of the impact of such testing across a variety of patient populations is needed. METHODS: SARS-CoV-2 nucleic acid amplification admission testing results for all asymptomatic patients across 4 distinct inpatient facilities between April 20, 2020, and June 14, 2021, were analyzed. Positivity rates and the number needed to test (NNT) to identify 1 asymptomatic infected patient were calculated. Admission results were compared to COVID-19 community incidence rates for the system's surrounding metropolitan service area. Using a national survey of hospital epidemiologists, a clinically meaningful NNT of 1:100 was identified. RESULTS: In total, 51,187 tests were collected (positivity rate, 1.8%). During periods of high transmission, the NNT met the clinically relevant threshold in all populations. The NNT approached or met the threshold for most locations during periods of lower transmission. For all transmission levels, the NNT for fully vaccinated patients did not meet the threshold. CONCLUSIONS: Implementing an asymptomatic patient admission testing program can provide clinically relevant data based on the NNT, even during periods of lower transmission and among different patient populations. Limiting admission testing to non-fully vaccinated patients during periods of lower transmission may be a strategy to address resource concerns around this practice. Although the impact of such testing on healthcare-associated COVID-19 among patients and healthcare workers could not be clearly determined, these data provide important information as facilities weigh the costs and benefits of such testing.


Sujet(s)
COVID-19 , Humains , COVID-19/diagnostic , COVID-19/épidémiologie , SARS-CoV-2 , Infections asymptomatiques/épidémiologie , Dépistage de la COVID-19 , Hospitalisation
8.
Infect Control Hosp Epidemiol ; 44(1): 2-7, 2023 01.
Article de Anglais | MEDLINE | ID: mdl-36539917

RÉSUMÉ

Testing of asymptomatic patients for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) (ie, "asymptomatic screening) to attempt to reduce the risk of nosocomial transmission has been extensive and resource intensive, and such testing is of unclear benefit when added to other layers of infection prevention mitigation controls. In addition, the logistic challenges and costs related to screening program implementation, data noting the lack of substantial aerosol generation with elective controlled intubation, extubation, and other procedures, and the adverse patient and facility consequences of asymptomatic screening call into question the utility of this infection prevention intervention. Consequently, the Society for Healthcare Epidemiology of America (SHEA) recommends against routine universal use of asymptomatic screening for SARS-CoV-2 in healthcare facilities. Specifically, preprocedure asymptomatic screening is unlikely to provide incremental benefit in preventing SARS-CoV-2 transmission in the procedural and perioperative environment when other infection prevention strategies are in place, and it should not be considered a requirement for all patients. Admission screening may be beneficial during times of increased virus transmission in some settings where other layers of controls are limited (eg, behavioral health, congregate care, or shared patient rooms), but widespread routine use of admission asymptomatic screening is not recommended over strengthening other infection prevention controls. In this commentary, we outline the challenges surrounding the use of asymptomatic screening, including logistics and costs of implementing a screening program, and adverse patient and facility consequences. We review data pertaining to the lack of substantial aerosol generation during elective controlled intubation, extubation, and other procedures, and we provide guidance for when asymptomatic screening for SARS-CoV-2 may be considered in a limited scope.


Sujet(s)
COVID-19 , SARS-CoV-2 , Humains , COVID-19/diagnostic , COVID-19/prévention et contrôle , Gouttelettes et aérosols respiratoires , Établissements de santé , Prévention des infections/méthodes
9.
Infect Control Hosp Epidemiol ; 43(12): 1822-1827, 2022 12.
Article de Anglais | MEDLINE | ID: mdl-35190002

RÉSUMÉ

OBJECTIVE: Although a growing number of healthcare facilities are implementing healthcare personnel (HCP) coronavirus disease 2019 (COVID-19) vaccination requirements, vaccine exemption request management as a part of such programs is not well described. DESIGN: Cross-sectional survey. PARTICIPANTS: Infectious disease (ID) physician members of the Emerging Infections Network with infection prevention or hospital epidemiology responsibilities. METHODS: Eligible persons were sent a web-based survey focused on hospital plans and practices around exemption allowances from HCP COVID-19 vaccine requirements. RESULTS: Of the 695 ID physicians surveyed, 263 (38%) responded. Overall, 160 respondent institutions (92%) allowed medical exemptions, whereas 132 (76%) allowed religious exemptions. In contrast, only 14% (n = 24) allowed deeply held personal belief exemptions. The types of medical exemptions allowed varied considerably across facilities, with allergic reactions to the vaccine or its components accepted by 145 facilities (84%). For selected scenarios commonly used as the basis for religious and deeply held personal belief exemption requests, 144 institutions (83%) would not approve exemptions focused on concerns regarding right of consent or violations of freedom of personal choice, and 140 institutions (81%) would not approve exemptions focused on introducing foreign substances into one's body or the sanctity of the body. Most respondents noted plans for additional infection prevention interventions for HCP who received an exemption for COVID-19 vaccination. CONCLUSIONS: Although many respondent institutions allowed exemptions from HCP COVID-19 vaccination requirements, the types of exemptions allowed and how the exemption programs were structured varied widely.


Sujet(s)
COVID-19 , Vaccins , Humains , Vaccins contre la COVID-19/usage thérapeutique , Études transversales , COVID-19/prévention et contrôle , Vaccination , Prestations des soins de santé
10.
Infect Control Hosp Epidemiol ; 43(2): 156-166, 2022 02.
Article de Anglais | MEDLINE | ID: mdl-33487199

RÉSUMÉ

This SHEA white paper identifies knowledge gaps and challenges in healthcare epidemiology research related to coronavirus disease 2019 (COVID-19) with a focus on core principles of healthcare epidemiology. These gaps, revealed during the worst phases of the COVID-19 pandemic, are described in 10 sections: epidemiology, outbreak investigation, surveillance, isolation precaution practices, personal protective equipment (PPE), environmental contamination and disinfection, drug and supply shortages, antimicrobial stewardship, healthcare personnel (HCP) occupational safety, and return to work policies. Each section highlights three critical healthcare epidemiology research questions with detailed description provided in supplementary materials. This research agenda calls for translational studies from laboratory-based basic science research to well-designed, large-scale studies and health outcomes research. Research gaps and challenges related to nursing homes and social disparities are included. Collaborations across various disciplines, expertise and across diverse geographic locations will be critical.


Sujet(s)
COVID-19 , Prestations des soins de santé , Personnel de santé , Humains , Pandémies , Équipement de protection individuelle , SARS-CoV-2
11.
Infect Control Hosp Epidemiol ; 43(9): 1256-1258, 2022 09.
Article de Anglais | MEDLINE | ID: mdl-33866989

RÉSUMÉ

We surveyed infectious disease specialists about early coronavirus disease 2019 (COVID-19) vaccination preparedness. Almost all responding institutions rated their facility's preparedness plan as either excellent or adequate. Vaccine hesitancy and concern about adverse reactions were the most commonly anticipated barriers to COVID-19 vaccination. Only 60% believed that COVID-19 vaccination should be mandatory.


Sujet(s)
COVID-19 , COVID-19/prévention et contrôle , Vaccins contre la COVID-19 , Hôpitaux , Humains , Politique (principe) , Vaccination
12.
Infect Dis Clin North Am ; 35(4): 1055-1075, 2021 12.
Article de Anglais | MEDLINE | ID: mdl-34752220

RÉSUMÉ

Health care-acquired viral respiratory infections are common and cause increased patient morbidity and mortality. Although the threat of viral respiratory infection has been underscored by the coronavirus disease 2019 (COVID-19) pandemic, respiratory viruses have a significant impact in health care settings even under normal circumstances. Studies report decreased nosocomial transmission when aggressive infection control measures are implemented, with more success noted when using a multicomponent approach. Influenza vaccination of health care personnel furthers decrease rates of transmission; thus, mandatory vaccination is becoming more common. This article discusses the epidemiology, transmission, and control of health care-associated respiratory viral infections.


Sujet(s)
Infection croisée/prévention et contrôle , Infection croisée/virologie , Infections de l'appareil respiratoire/prévention et contrôle , Infections de l'appareil respiratoire/virologie , COVID-19/épidémiologie , COVID-19/prévention et contrôle , COVID-19/transmission , Infection croisée/épidémiologie , Infection croisée/transmission , Adhésion aux directives , Personnel de santé/normes , Humains , Prévention des infections/normes , Infections de l'appareil respiratoire/épidémiologie , Infections de l'appareil respiratoire/transmission , SARS-CoV-2/pathogénicité , Vaccination , Virus/classification , Virus/pathogénicité
14.
J Patient Saf ; 17(8): e1272-e1277, 2021 12 01.
Article de Anglais | MEDLINE | ID: mdl-29683875

RÉSUMÉ

OBJECTIVES: Following institution of a hand hygiene (HH) program at an academic medical center, HH compliance increased from 58% to 92% for 3 years. Some inpatient units modeled early, sustained increases, and others exhibited protracted improvement rates. We examined the association between patterns of HH compliance improvement and unit characteristics. METHODS: Adult inpatient units (N = 35) were categorized into the following three tiers based on their pattern of HH compliance: early adopters, nonsustained and late adopters, and laggards. Unit-based culture measures were collected, including nursing practice environment scores (National Database of Nursing Quality Indicators [NDNQI]), patient rated quality and teamwork (Hospital Consumer Assessment of Healthcare Provider and Systems), patient complaint rates, case mix index, staff turnover rates, and patient volume. Associations between variables and the binary outcome of laggard (n = 18) versus nonlaggard (n = 17) were tested using a Mann-Whitney U test. Multivariate analysis was performed using an ordinal regression model. RESULTS: In direct comparison, laggard units had clinically relevant differences in NDNQI scores, Hospital Consumer Assessment of Healthcare Provider and Systems scores, case mix index, patient complaints, patient volume, and staff turnover. The results were not statistically significant. In the multivariate model, the predictor variables explained a significant proportion of the variability associated with laggard status, (R2 = 0.35, P = 0.0481) and identified NDNQI scores and patient complaints as statistically significant. CONCLUSIONS: Uptake of an HH program was associated with factors related to a unit's safety culture. In particular, NDNQI scores and patient complaint rates might be used to assist in identifying units that may require additional attention during implementation of an HH quality improvement program.


Sujet(s)
Infection croisée , Hygiène des mains , Adulte , Infection croisée/prévention et contrôle , Adhésion aux directives , Personnel de santé , Humains , Prévention des infections , Patients hospitalisés
15.
Infect Control Hosp Epidemiol ; 42(4): 381-387, 2021 04.
Article de Anglais | MEDLINE | ID: mdl-32900402

RÉSUMÉ

OBJECTIVE: To characterize associations between exposures within and outside the medical workplace with healthcare personnel (HCP) SARS-CoV-2 infection, including the effect of various forms of respiratory protection. DESIGN: Case-control study. SETTING: We collected data from international participants via an online survey. PARTICIPANTS: In total, 1,130 HCP (244 cases with laboratory-confirmed COVID-19, and 886 controls healthy throughout the pandemic) from 67 countries not meeting prespecified exclusion (ie, healthy but not working, missing workplace exposure data, COVID symptoms without lab confirmation) were included in this study. METHODS: Respondents were queried regarding workplace exposures, respiratory protection, and extra-occupational activities. Odds ratios for HCP infection were calculated using multivariable logistic regression and sensitivity analyses controlling for confounders and known biases. RESULTS: HCP infection was associated with non-aerosol-generating contact with COVID-19 patients (adjusted OR, 1.4; 95% CI, 1.04-1.9; P = .03) and extra-occupational exposures including gatherings of ≥10 people, patronizing restaurants or bars, and public transportation (adjusted OR range, 3.1-16.2). Respirator use during aerosol-generating procedures (AGPs) was associated with lower odds of HCP infection (adjusted OR, 0.4; 95% CI, 0.2-0.8, P = .005), as was exposure to intensive care and dedicated COVID units, negative pressure rooms, and personal protective equipment (PPE) observers (adjusted OR range, 0.4-0.7). CONCLUSIONS: COVID-19 transmission to HCP was associated with medical exposures currently considered lower-risk and multiple extra-occupational exposures, and exposures associated with proper use of appropriate PPE were protective. Closer scrutiny of infection control measures surrounding healthcare activities and medical settings considered lower risk, and continued awareness of the risks of public congregation, may reduce the incidence of HCP infection.


Sujet(s)
COVID-19/transmission , Transmission de maladie infectieuse du patient au professionnel de santé/prévention et contrôle , Adulte , Sujet âgé , COVID-19/prévention et contrôle , Études cas-témoins , Femelle , Santé mondiale/statistiques et données numériques , Humains , Transmission de maladie infectieuse du patient au professionnel de santé/statistiques et données numériques , Modèles logistiques , Mâle , Adulte d'âge moyen , Exposition professionnelle/prévention et contrôle , Exposition professionnelle/statistiques et données numériques , Équipement de protection individuelle/statistiques et données numériques , Équipement de protection individuelle/virologie , Respirateurs purificateurs d'air/statistiques et données numériques , Respirateurs purificateurs d'air/virologie , Jeune adulte
16.
Infect Control Hosp Epidemiol ; 42(1): 1-5, 2021 01.
Article de Anglais | MEDLINE | ID: mdl-32938509

RÉSUMÉ

SHEA endorses adhering to the recommendations by the CDC and ACIP for immunizations of all children and adults. All persons providing clinical care should be familiar with these recommendations and should routinely assess immunization compliance of their patients and strongly recommend all routine immunizations to patients. All healthcare personnel (HCP) should be immunized against vaccine-preventable diseases as recommended by the CDC/ACIP (unless immunity is demonstrated by another recommended method). SHEA endorses the policy that immunization should be a condition of employment or functioning (students, contract workers, volunteers, etc) at a healthcare facility. Only recognized medical contraindications should be accepted for not receiving recommended immunizations.


Sujet(s)
Prestations des soins de santé , Immunisation , Adulte , , Enfant , Contre-indications , Humains , Politique (principe) , États-Unis
17.
Infect Control Hosp Epidemiol ; 42(5): 507-512, 2021 05.
Article de Anglais | MEDLINE | ID: mdl-33118915

RÉSUMÉ

OBJECTIVE: Vanderbilt University Medical Center (VUMC) requires that all faculty and staff receive the seasonal influenza vaccine annually or receive an approved vaccine exemption, either for a medical or deeply held religious or personal belief. We sought to understand the underlying principles behind these exemption requests and their interaction with a multidisciplinary exemption review process. DESIGN: All of the personal and religious exemption requests at VUMC for 3 consecutive influenza seasons from 2015 to 2018 were analyzed, categorizing these requests by 1 of 12 standardized employee categories and 1 of 18 unique reasons for vaccine exemption. SETTING: Tertiary-care academic medical center. PARTICIPANTS: Healthcare personnel (HCP). RESULTS: Among the 3 influenza seasons, 1.1%-2.1% of all VUMC HCP requested religious or personal exemption from vaccination. The frequency of religious and personal exemption approval increased annually from 296 of 452 (65.5%) to 196 of 248 (80.2%) to 283 of 323 (87.6%) over the 3 seasons, representing a statistically significant increase each year. Of the 5 most common reasons against vaccination, 4 were explicitly religious in nature; the most common reason was that the "body is a temple or sacred." Nonclinical staff submitted the most religious and personal exemption requests of any job category, submitting approximately one-third of all requests every year. CONCLUSIONS: These results demonstrate how detailed the personal or religious convictions behind vaccine avoidance can be among HCP and how vaccine avoidance stems from much more than simple misinformation regarding vaccination. The intersection between misinformation and personal or religious beliefs provides a unique opportunity to address HCP opinions toward vaccination in an exemption and appeals process like the one described here.


Sujet(s)
Vaccins antigrippaux , Grippe humaine , Prestations des soins de santé , Personnel de santé , Humains , Grippe humaine/prévention et contrôle , Saisons , Vaccination
18.
Infect Control Hosp Epidemiol ; 42(5): 513-518, 2021 05.
Article de Anglais | MEDLINE | ID: mdl-33168113

RÉSUMÉ

OBJECTIVE: Evaluation of a mandatory immunization program to increase and sustain high immunization coverage for healthcare personnel (HCP). DESIGN: Descriptive study with before-and-after analysis. SETTING: Tertiary-care academic medical center. PARTICIPANTS: Medical center HCP. METHODS: A comprehensive mandatory immunization initiative was implemented in 2 phases, starting in July 2014. Key facets of the initiative included a formalized exemption review process, incorporation into institutional quality goals, data feedback, and accountability to support compliance. RESULTS: Both immunization and overall compliance rates with targeted immunizations increased significantly in the years after the implementation period. The influenza immunization rate increased from 80% the year prior to the initiative to >97% for the 3 subsequent influenza seasons (P < .0001). Mumps, measles and varicella vaccination compliance increased from 94% in January 2014 to >99% by January 2017, rubella vaccination compliance increased from 93% to 99.5%, and hepatitis B vaccination compliance from 95% to 99% (P < .0001 for all comparisons). An associated positive effect on TB testing compliance, which was not included in the mandatory program, was also noted; it increased from 76% to 92% over the same period (P < .0001). CONCLUSIONS: Thoughtful, step-wise implementation of a mandatory immunization program linked to professional accountability can be successful in increasing immunization rates as well as overall compliance with policy requirements to cover all recommended HCP immunizations.


Sujet(s)
Grippe humaine , Prestations des soins de santé , Humains , Programmes de vaccination , Grippe humaine/prévention et contrôle , Responsabilité sociale , Vaccination
19.
Infect Control Hosp Epidemiol ; 41(5): 505-509, 2020 05.
Article de Anglais | MEDLINE | ID: mdl-32172696

RÉSUMÉ

OBJECTIVE: To identify risk factors of patients placed in airborne infection isolation (AII) for possible pulmonary tuberculosis (TB) to better predict TB diagnosis and allow more judicious use of AII. METHODS: Case-control, retrospective study at a single tertiary-care academic medical center. The study included all adult patients admitted from October 1, 2014, through October 31, 2017, who were placed in AII for possible pulmonary TB. Cases were defined as those ultimately diagnosed with pulmonary TB. Controls were defined as those not diagnosed with pulmonary TB. Those with TB diagnosed prior to admission were excluded. In total, 662 admissions (558 patients) were included. RESULTS: Overall, 15 cases of pulmonary TB were identified (2.7%); of these, 2 were people living with human immunodeficiency virus (HIV; PLWH). Statistical analysis was limited by low case number. Those diagnosed with pulmonary TB were more likely to have been born outside the United States (53% vs 13%; P < .001) and to have had prior positive TB testing, regardless of prior treatment (50% vs 19%; P = .015). A multivariate analysis using non-US birth and prior positive TB testing predicted an 18.2% probability of pulmonary TB diagnosis when present, compared with 1.0% if both factors were not present. CONCLUSIONS: The low number of pulmonary TB cases indicated AII overuse, especially in PLWH, and more judicious use of AII is warranted. High-risk groups, including those born outside the United States and those with prior positive TB testing, should be considered for AII in the appropriate clinical setting.


Sujet(s)
Infection croisée/prévention et contrôle , Prévention des infections/méthodes , Exposition professionnelle/prévention et contrôle , Isolement du patient/méthodes , Tuberculose pulmonaire/prévention et contrôle , Adulte , Sujet âgé , Polluants atmosphériques d'origine professionnelle , Études cas-témoins , Infection croisée/microbiologie , Femelle , Humains , Mâle , Adulte d'âge moyen , Tennessee , Centres de soins tertiaires , Tuberculose pulmonaire/diagnostic
20.
Ann Intern Med ; 172(1): 30-34, 2020 01 07.
Article de Anglais | MEDLINE | ID: mdl-31739344

RÉSUMÉ

Infection control is a complex task that spans people, products, and practices in diverse settings. For years, the Healthcare Infection Control Practices Advisory Committee (HICPAC) has provided advice and guidance to the Centers for Disease Control and Prevention (CDC) on how best to prevent infections. These recommendations have focused largely on health care delivery practices and occasionally on general categories of products. With an influx of novel infection control products and growing use of these products by frontline clinicians, an efficient process for developing transparent, rigorous product recommendations that includes myriad data sources was necessary. To address this gap, the CDC asked HICPAC to develop a process that would help inform committees considering product-related recommendations. This article describes the process to develop this approach and provides an outline of how the tool may be used when products with infection control claims are recommended in guidelines or recommendations for infection prevention.


Sujet(s)
Infection croisée/prévention et contrôle , Désinfection/méthodes , Prévention des infections/méthodes , Comités consultatifs , , Désinfection/statistiques et données numériques , Humains , Prévention des infections/normes , Évaluation de la technologie biomédicale/méthodes , Évaluation de la technologie biomédicale/normes , États-Unis
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE